{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-008027","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2022-11-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.485097+00:00","generated_at":"2026-06-21T13:25:45.373397+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Odyssey Health acquires option to purchase PRV-001 patents from Prevacus for 1M shares","bullets":["Option to buy 100% of worldwide patents to PRV-001 and an Enantiomer from Prevacus.","Consideration for option: 1,000,000 shares of Odyssey common stock.","If exercised, asset purchase price: 2M shares for PRV-001, 1M shares for Enantiomer.","Option exercisable within 180 days of Nov 22, 2022; closing within 90 days after exercise.","Odyssey will also enter an asset purchase agreement upon exercise."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-008027","json":"https://secwatch.observer/filing/0001683168-22-008027.json","markdown":"https://secwatch.observer/filing/0001683168-22-008027.md","text":"https://secwatch.observer/filing/0001683168-22-008027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822008027/0001683168-22-008027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822008027/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:25:45.373397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"069238f7ad7a40b42ae2ad06915eecea032c8c74","claim":"Odyssey Health, Inc. entered into Option to Purchase Intellectual Property Agreement with Prevacus, Inc. (effective 2022-11-21).","evidence_excerpt":"On November 21, 2022, Odyssey Health, Inc. (the “Company” “Odyssey”) entered into an Option to Purchase Intellectual Property Agreement (the “Option Agreement”) with Prevacus, Inc. (“Prevacus”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822008027/0001683168-22-008027-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Prevacus, Inc."},{"label":"Effective","value":"2022-11-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}